U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of about $30 billion, a person familiar with the matter said on Monday. The ...

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

Jeffrey William Henderson, a director at Becton Dickinson & Co (NYSE:BDX), recently acquired 1,500 shares of the company's common stock. The purchase, which took place on February 10, 2025, was made ...

Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company (BDX) is a global leader in medical technology ...

StockNews.com upgraded shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) from a hold rating to a buy rating in a research note released on Wednesday morning. Separately ...

Shares of Becton Dickinson & Co. BDX slipped 1.60% to $225.85 Wednesday, on what proved to be an all-around rough trading ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

Becton Dickinson & Co. closed 2.75% below its 52-week high of $251.99, which the company reached on February 3rd.

Shares of Becton Dickinson & Co. BDX slid 7.28% to $227.21 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.36% to 6,083 ...